| NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
| NCT02569645 | Rectal Cancer | Drug: Rosuvastatin | AHS Cancer Control Alberta|Ozmosis Research Inc. | Phase 2 | 2015-11-01 | 2016-09-19 |
| NCT01218347 | Organic Anion Transporting Polypeptide1B1 (OATP1B1)|Rosuvastatin | Drug: Rosuvastatin | Seoul National University Hospital | Phase 4 | 2010-10-01 | 2011-01-04 |
| NCT00766025 | CYP2C19 Poor|Extensive Metabolizers | Drug: Rosuvastatin Calcium | AstraZeneca | Phase 1 | 2008-09-01 | 2009-02-27 |
| NCT01524601 | Disorder Related to Renal Transplantation|Hypercholesterolemia | Drug: Rosuvastatin | University of Oslo School of Pharmacy|Oslo University Hospital | Phase 4 | 2012-02-01 | 2012-10-11 |
| NCT02106767 | Healthy | Drug: Rosuvastatin|Drug: Rosuvastatin plus rifampin | University of California, San Francisco | Phase 1 | 2014-11-01 | 2015-12-01 |
| NCT01466608 | Hypercholesterolemia | Drug: Rosuvastatin | Seoul National University Hospital | Phase 4 | 2011-11-01 | 2014-05-15 |
| NCT01490398 | Hypertension|Cardiovascular Risk Factors | Drug: Rosuvastatin | Asan Medical Center|AstraZeneca | Phase 4 | 2011-12-01 | 2014-05-08 |
| NCT02215174 | Statin Pharmacokinetics Pre and Post Gastric Bypass Surgery | Drug: Rosuvastatin | University of California, San Francisco|E-DA Hospital | Phase 1 | 2015-02-01 | 2015-04-24 |
| NCT00463606 | Hypercholesterolemia|Dyslipidemia | Drug: ABT-335 and rosuvastatin calcium|Drug: ABT-335|Drug: rosuvastatin calcium | AstraZeneca | Phase 3 | 2007-04-01 | 2012-09-27 |
| NCT02705547 | Friedreich Ataxia | Drug: Rosuvastatin | Children's Hospital of Philadelphia|Friedreich's Ataxia Research Alliance | Early Phase 1 | 2016-05-01 | 2017-03-15 |
| NCT00986999 | HIV Infections|Cardiovascular Disease | Drug: rosuvastatin | University of Hawaii | Phase 2|Phase 3 | 2009-09-01 | 2015-01-20 |
| NCT00660764 | Hypercholesterolemia|Coronary Heart Disease|Peripheral Vascular Disease|Cerebrovascular Accident|Diabetes | Drug: Rosuvastatin | AstraZeneca | | 2003-05-01 | 2009-03-13 |
| NCT02284503 | Non-ST-elevation Acute Coronary Syndromes | Drug: Rosuvastatin | Shanghai Zhongshan Hospital | Phase 4 | 2014-11-01 | 2014-11-03 |
| NCT00240318 | Coronary Arteriosclerosis | Drug: Rosuvastatin calcium | AstraZeneca | Phase 3 | 2002-11-01 | 2010-11-18 |
| NCT01382277 | Hyperlipidemia|Coronary Artery Disease | Drug: Rosuvastatin | Peking University First Hospital | Phase 4 | 2011-03-01 | 2011-06-23 |
| NCT00225589 | Hypercholesteremia | Drug: Rosuvastatin calcium | AstraZeneca | Phase 3 | 2002-08-01 | 2010-11-18 |
| NCT02083627 | Drug-Drug Interaction (DDI)|Intestinal Absorption|Healthy Subjects|Pharmacokinetics of Rosuvastatin|Pharmacokinetics of Fidaxomicin | Drug: rosuvastatin|Drug: fidaxomicin | Astellas Pharma Europe B.V.|Cubist Pharmaceuticals LLC|Astellas Pharma Inc | Phase 1 | 2013-02-01 | 2014-05-19 |
| NCT01863914 | End-stage Kidney Disease|Diabetes Mellitus|Arteriovenous Fistula | Drug: Rosuvastatin | National Cheng-Kung University Hospital | Phase 2 | 2012-11-01 | 2016-09-24 |
| NCT00966472 | Squamous Cell Carcinoma|Non-Small Cell Lung Cancer | Drug: Erlotinib + Rosuvastatin | Ottawa Hospital Research Institute|Ozmosis Research Inc. | Phase 1 | 2009-03-01 | 2015-04-21 |
| NCT00984932 | Systemic Sclerosis | Drug: Rosuvastatin | Faculty of Medicine, University of Alexandria | Phase 3 | 2008-09-01 | 2009-09-24 |
| NCT03007524 | Acute Coronary Syndrome | Drug: High dose Rosuvastatin|Drug: Low dose Rosuvastatin | Nanjing First Hospital, Nanjing Medical University | Phase 4 | 2016-07-01 | 2017-02-19 |
